Other Issues

Browse Other Issues Content

CHPA's voluntary plan to address concerns surrounding the safety and efficacy of OTC oral pediatric cough and cold medicines. CHPA, on behalf of its member companies, commits to the following initiatives.

Nov 28, 2007

The members of the Consumer Healthcare Products Association appreciate the opportunity to provide comments on the interim final rule on the petition to request an exemption from 100 percent identity testing for dietary ingredients.

Aug 9, 2007

CHPA comments on the proposed rule, which proposes new warning and other labeling requirements for internal analgesic, antipyretic, and antirheumatic OTC drug products.

May 25, 2007

FDA issued a proposed rule on labeling requirements for OTC human drugs. The announcement proposed a definition for “convenience-size” OTC drug packages as well as the option of alternative labeling requirements for these products. CHPA welcomes the opportunity to comment on the proposed rule changes.

May 7, 2007

CHPA welcomes the opportunity to comment on the proposed rule change on labeling requirements for OTC human drugs.

Mar 23, 2007

Letter to the FDA's LT Darrell Lyons requesting additional time to address the Nonprescription Drugs Advisory Committee.

Sep 11, 2006

CHPA appreciates the comments of FDA in the February 2006, feedback letter and understands that these comments are FDA’s best advice on designing a protocol to address the safety and efficacy of benzocaine. We have included a revised final protocol for your final review.

Jun 5, 2006

CHPA has supported and continues to support the timely provision of complete and accurate product information to healthcare professionals and patients in an easily accessible format, and commends the Agency for considering new approaches to disseminating emerging drug safety-related data.

Aug 8, 2005

CHPA appreciates the opportunity to provide comments concerning U.S. Government positions in preparation for the 33rd session of the Codex Committee on Food Labelling of the Codex Alimentarius Commission.

Apr 13, 2005

In considering the safety of NSAIDs, the use of OTC NSAIDs should be clearly distinguished from long-term prescription NSAID use. OTC medicines have a different overall benefit-to-risk equation and a wider margin of safety than prescription NSAIDs.

Feb 17, 2005

Filter Results